| [1] |
VASHI B, KHOSROSHAHI A. IgG4-related disease with emphasis on its gastrointestinal manifestation[J]. Gastroenterol Clin North Am, 2019, 48(2): 291-305. DOI: 10.1016/j.gtc.2019.02.008. |
| [2] |
FUJIMORI N, ITO T, IGARASHI H, et al. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease[J]. World J Gastroenterol, 2013, 19(1): 35-41. DOI: 10.3748/wjg.v19.i1.35. |
| [3] |
HAMANO H, KAWA S, HORIUCHI A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis[J]. N Engl J Med, 2001, 344(10): 732-738. DOI: 10.1056/NEJM200103083441005. |
| [4] |
HAMANO H, KAWA S, OCHI Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis[J]. Lancet, 2002, 359(9315): 1403-1404. DOI: 10.1016/s0140-6736(02)08359-9. |
| [5] |
KAMISAWA T, FUNATA N, HAYASHI Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease[J]. J Gastroenterol, 2003, 38(10): 982-984. DOI: 10.1007/s00535-003-1175-y. |
| [6] |
KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699. DOI: 10.1002/art.39132. |
| [7] |
URBAN ML, PALMISANO A, NICASTRO M, et al. Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach[J]. Rev Med Interne, 2015, 36(1): 15-21. DOI: 10.1016/j.revmed.2014.10.008. |
| [8] |
LIU YS, ZHAO XN, WANG YY, et al. Ultrasonographic value of idiopathic retroperitoneal fibrosis[J]. Chin J Ultrasound Med, 2018, 34(12): 1105-1107. DOI: 10.3969/j.issn.1002-0101.2018.12.016. |
| [9] |
|
| [10] |
CHAN A, MUDHAR H, SHEN SY, et al. Serum IgG2 and tissue IgG2 plasma cell elevation in orbital IgG4-related disease (IgG4-RD): Potential use in IgG4-RD assessment[J]. Br J Ophthalmol, 2017, 101(11): 1576-1582. DOI: 10.1136/bjophthalmol-2017-310148. |
| [11] |
KOTANI S, WAKAMATSU R, ITOH A, et al. Proteinase 3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) positive IgG4-related retroperitoneal fibrosis: utility of PET-CT with 18F-fluorodeoxy glucose (FDG)[J]. Intern Med, 2012, 51(7): 755-758. DOI: 10.2169/internalmedicine.51.6599. |
| [12] |
BRANDT AS, KAMPER L, KUKUK S, et al. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis[J]. Urol Int, 2014, 93(3): 320-325. DOI: 10.1159/000357814. |
| [13] |
van der BILT FE, HENDRIKSZ TR, van der MEIJDEN WA, et al. Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy[J]. Clin Kidney J, 2016, 9(2): 184-191. DOI: 10.1093/ckj/sfv148. |
| [14] |
WALLWORK R, WALLACE Z, PERUGINO C, et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis[J]. Medicine (Baltimore), 2018, 97(42): e12631. DOI: 10.1097/MD.0000000000012631 |
DownLoad:
